View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

New Vishay Intertechnology Silicon PIN Photodiode Delivers Smaller Siz...

New Vishay Intertechnology Silicon PIN Photodiode Delivers Smaller Size and Enhanced Sensitivity for Biomedical Applications Device Offers Large Sensitive Area of 2.8 mm² and High Light Current to 16 μA in Compact 3.2 mm by 2.0 mm by 0.6 mm Form Factor MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc. (NYSE: VSH) today broadens its optoelectronics portfolio with the introduction of a new high speed silicon PIN photodiode with enhanced sensitivity to visible and infrared light. Featuring a compact 3.2 mm by 2.0 mm top-view, surface-mount package with a low 0.6 ...

 PRESS RELEASE

Lantronix CEO to Participate in Craig-Hallum, ROTH and Headgate Partne...

Lantronix CEO to Participate in Craig-Hallum, ROTH and Headgate Partners Investor Conferences IRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions powering Edge AI applications, today announced that its CEO Saleel Awsare will participate in three upcoming investor conferences: — Tuesday, Nov. 18, New York City One-on-one meetings with CEO Saleel Awsare and Brent Stringham, CFOTo register for the conference, click . — Wednesday, Nov. 19, New York City One-on-one meetings with CEO Saleel Awsare and Brent Stringham,...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: November 7, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 8, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Full House Resorts Announces Strong Third Quarter Results

Full House Resorts Announces Strong Third Quarter Results - American Place Casino Continued Its Strong Growth, With Revenues Increasing 14.0% to a New Property Record in the Third Quarter of 2025 - Consolidated Operating Income Rose 40.3% to $3.4 Million in the Third Quarter of 2025; Net Loss Improved to $(7.7) Million from $(8.5) Million - Adjusted EBITDA Increased 26.1% to $14.8 Million in the Third Quarter of 2025, Reflecting Strong Results at American Place and a $2.1 Million Contribution from Chamonix/Bronco Billy’s LAS VEGAS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Full House Resorts,...

 PRESS RELEASE

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidanc...

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings per diluted share1 increased to $7.40 - $7.65 (previously $6.70 - $7.00) Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended Sept...

 PRESS RELEASE

Lantronix Reports Fiscal First Quarter 2026 Financial Results

Lantronix Reports Fiscal First Quarter 2026 Financial Results First Quarter 2026 Net Revenue of $29.8 MillionFirst Quarter 2026 GAAP EPS of ($0.04) First Quarter 2026 Non-GAAP EPS of $0.04 Grew Drone OEM Engagements to 17 in Q1, Underscoring Demand in the UAS Market IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions powering Edge AI applications, today reported results for the fiscal first quarter ended Sept. 30, 2025. Management Commentary “Fiscal 2026 is off to a strong start, with revenue and earnings per shar...

 PRESS RELEASE

Newtek Merchant Solutions Hires Justine Martin as Chief Revenue Office...

Newtek Merchant Solutions Hires Justine Martin as Chief Revenue Officer BOCA RATON, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (“NewtekOne” or “Company”) (NASDAQ: NEWT) announced that its wholly owned subsidiary, Newtek Merchant Solutions, LLC (“NMS”), has hired Justine Martin as Chief Revenue Officer. In addition to teaching, training, and mentoring staff of NMS, Ms. Martin will focus on improving integration between the Company’s payments, banking, and lending functions. Ms. Martin will report to Barry Sloane, NMS’ Chief Executive Officer, and Michael Gleason, President and...

 PRESS RELEASE

Vishay Intertechnology Reports Third Quarter 2025 Results

Vishay Intertechnology Reports Third Quarter 2025 Results MALVERN, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc., (NYSE: VSH), one of the world's largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal third quarter ended September 27, 2025. Highlights 3Q 2025 revenues of $790.6 millionGross margin was 19.5% and included the negative impact of approximately 150 basis points related to Newport3Q 2025 GAAP loss per share of $(0.06)3Q 2025 Adjusted EPS of $0.043Q 2025 book-to-bill of 0.97 with boo...

 PRESS RELEASE

The Tile Shop Reports Third Quarter 2025 Results

The Tile Shop Reports Third Quarter 2025 Results MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, today announced results for its third quarter ended September 30, 2025. Third Quarter 2025 Summary Net Sales Decreased 1.7%Comparable Store Sales Decreased 1.4% Gross Margin of 62.9%Net Loss of $1.6 Million and Adjusted EBITDA of $2.0 MillionNo Debt Outstanding and $24.1 million of Cash at Quarter-End Management Commentary – Cabell Lolmaugh, CEO “Unit volumes inc...

 PRESS RELEASE

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial...

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The tables have been added and the corrected release follows: NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination port...

 PRESS RELEASE

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study...

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the first patient has been dosed in its Phase 2 pHalcon-EoE-2...

 PRESS RELEASE

Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and...

Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-endNXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dosingNXP900 clinical drug-drug interaction study in healthy volunteer...

 PRESS RELEASE

Phathom Pharmaceuticals to Participate in Upcoming Investor Conference...

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences: Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MADate: Monday, November 10, 2025Live Webcast: 3:00 pm ESTManagement to participate in one-on...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch